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Abstract
Background: Pharmacological intervention of redox balance in cancer cells often results in oxidative stress-mediated
apoptosis, attracting much attention for the development of a new generation of targeted therapy in cancer. However, little
is known about mechanisms underlying the conversion from oxidative signaling to downstream activities leading cells to
death.
Methodology/Principal Findings: We here report a systematic detection of transcriptome changes in response to oxidative
signals generated in leukemia cells upon fenretinide treatment, implicating the occurrence of numerous stress-responsive
events during the fenretinide induced apoptosis, such as redox response, endoplasmic reticulum stress/unfolded protein
response, translational repression and proteasome activation. Moreover, the configuration of these relevant events is
primarily orchestrated by stress responsive transcription factors, as typically highlighted by NF-E2-related factor-2 (NRF2)
and heat shock factor 1 (HSF1). Several lines of evidence suggest that the coordinated regulation of these transcription
factors and thus their downstream genes are involved in converting oxidative signaling into downstream stress-responsive
events regulating pro-apoptotic and apoptotic activities at the temporal and spatial levels, typifying oxidative stress-
mediated programmed death rather than survival in cancer cells.
Conclusions/Significance: This study provides a roadmap for understanding oxidative stress-mediated apoptosis in cancer
cells, which may be further developed into more sophisticated therapeutic protocols, as implicated by synergistic induction
of cell apoptosis using proteasome inhibitors with fenretinide.
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Introduction
The development of cancer therapies can benefit from the
accumulated knowledge in cancer biology, particularly with
respect to cancer hallmarks such as self-sufficiency in growth
signals, evasion of programmed cell death and metastasis [1].
Recent experimental and clinical data provide compelling
evidence that the reduction/oxidation (redox) signaling pathways
may play an essential role in carcinogenesis and malignant
progression [2]. In general, malignant cells are intrinsically under
pro-oxidant microenvironment, with increased steady-state levels
of reactive oxygen species (ROS) [3], representing another
promising component of biological differences between cancer
and normal cells. Recently, new therapeutic intervention strategies
producing a state of selective oxidative stress in cancer cells have
gained importance [4].
Redox regulation has been shown to be an important
mechanism of malignant cell survival. Shifting the cellular redox
balance through pharmacologic manipulation in favor of increas-
ing intracellular ROS may lead to oxidative stress and subsequent
induction of apoptosis within cancer cells. The engagement of
apoptosis in cancer cells induced by ROS-generating agents is
probably accompanied by the activation of endoplasmic reticulum
(ER) stress. Apoptosis can be initiated by death receptors
stimulating the extrinsic pathway, or by perturbation of intracel-
lular homeostasis involving mitochondria-associated intrinsic
pathway and ER stress-mediated pathway. These initiating pro-
apoptotic signals finally converge on central executioner of
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7538apoptosis by the disruption of mitochondrial transmembrane
potential (MMP) in mitochondria as well as the activation of
caspase cascades. Reaching the level to an extent exceeding the
endurable redox threshold, ROS can act as specific signals
stimulating ER stress-mediated apoptosis specifically in cancer
cells. In response to various stimuli including oxidative stressors
[5,6], ER has evolved unfolded protein response (UPR) modulat-
ing several transcription factors (e.g., ATF6, XBP1 and CHOP) in
an attempt to adapt for survival or otherwise undergo apoptosis
facing prolonged UPR. However, there is limited knowledge about
mechanisms underlying the conversion from oxidative signaling to
downstream stress events leading cells to death. With the
availability of appropriate therapeutic ROS-generating agents,
systematic characterization of gene expression and the underlying
transcriptional regulation will be the key to the elucidation of such
conversion.
With the development of ROS-generating agents such as
arsenic trioxide (ATO) for the treatment of acute promyelocytic
leukemia (APL) [7], the possibility of exploiting selective oxidative
stress as apoptosis-inducing cancer therapy is the emerging as a
promising therapeutic option. Experimental data have show that
the therapeutic effectiveness of ATO is mediated by ROS
intracellular production and subsequent apoptosis [8]. Although
ROS-inducing agents like ATO have shown great potentials in the
treatment of malignant cells, the side effects remain to be fully
evaluated [9]. There is considerable interest in designing the most
rationale redox-active strategies with minimal in vivo side effects. In
this aspect, N-(4-hydroxyphenyl) retinamide (fenretinide), a
synthetic retinoid with several long-term clinical trials, is worthy
of further investigation [10]. Unlike such natural retinoids as
all-trans retinoic acid (ATRA), fenretinide exerts distinct biologic
effects, preferentially engaging the apoptotic pathway in many
tumor cells targeting ROS while maintaining its minimal in vivo
cytotoxicity to normal cells [11,12]. Mechanisms of fenretinide-
induced apoptosis have been intensively studied [13–15]. Recent
data suggest that this ROS-generating agent may perturb cellular
homeostasis and modulate the various stress-related genes,
implicating that the involvement of ROS-dependent ER stress
may render the susceptibility of cancer cells to fenretinide-induced
apoptosis [16]. However, the mechanisms by which ROS
formation leads to ER stress and cancer cell apoptosis are far
from clear. Detailed elucidation of these mechanistic links may
allow insight into oxidative stress-mediated apoptosis in cancer
cells and permit the optimization of cancer-specific targeting
therapies.
We speculate that cancer cells with predisposition of redox
signaling are most likely sensitive to oxidative stimuli from ROS-
generating agents such as fenretinide, undergoing oxidative stress-
mediated apoptosis. To precisely uncover regulatory mechanisms
underlying the conversion from oxidative signaling to downstream
stress events exerted on ER and eventually to death outcomes
rather than survival advantages, we employed integrative methods
of advanced data mining with microarray technology to profile
transcriptome changes in a fenretinide-sensitive cell line, and
found numerous temporal-spatial relationships between stress-
responsive events. Moreover, stress-responsive transcription fac-
tors, as highlighted by NF-E2-related factor-2 (NRF2) and heat
shock factor 1 (HSF1), play prominent roles in the configuration of
these relevant events. Validations through immunofluorescene and
chromatin immunoprecipitation assays and stress-related tran-
scriptome comparisons further provided evidence that these stress-
responsive regulators and thus their target genes are involved in
converting oxidative signaling into downstream stress activities
including redox response, ER stress/UPR and proteasome
activation, representing typical events of oxidative stress mediated
apoptosis in fenretinide-treated malignant cells.
Results
Fenretinide induces intracellular production of ROS and thus
apoptosis in a variety of malignancies including leukemia [10]. We
analyzed the antiproliferative and apoptotic effects of fenretinide
on leukemia-derived cell lines NB4, U937, and HL60, and found
that these cell lines underwent growth inhibition and apoptosis in
response to 1–2 mM of fenretinide, and that their susceptibilities
appeared to be correlated with levels of ROS (Supplementary
Figure S1). Based on its relatively high sensitivity to drug-induced
ROS generation and apoptosis, NB4 was chosen as a prototype
cell line for cellular and molecular assessments prior to detailed
transcriptome analysis. As shown in Figure 1A, NB4 cell growth
was inhibited by fenretinide treatment in a dose-dependent
manner. Treatment with a low dose (1 mM) of fenretinide
appeared to be sufficient to induce apoptosis in NB4 cells within
72 hours, as shown by mitochondrial membrane potential and
annexin V assays (Figures 1B and 1C). We further examined
intracellular ROS changes during this time course. Surprisingly,
we found that ROS changes were more complex than previously
recognized, displaying left-skewed bell-shape curve (Figure 1D). As
expected, ROS accumulated sharply, reaching a four-fold increase
compared to the basal levels within 6 hours of treatment, whereas
it unexpectedly decreased gradually thereafter to levels corre-
sponding roughly to twice the basal levels of untreated cells. This
data suggests the involvement of redox signaling in NB4 cells upon
fenretinide treatment. Fenretinide stimulation causes a rapid
accumulation of intracellular ROS, which may in turn activate
cellular mechanisms to reduce ROS levels. Also, the moderate
levels of intracellular ROS are probably required for fenretinide-
induced apoptosis.
Robust transcriptome profiling of fenretinide-induced
apoptosis
Time-series microarray hybridization, gene selection,
and identification of transcriptome features. To analyze
the detailed mechanisms underlying fenretinide-induced apoptosis,
we performed transcriptome profiling on samples of fenretinide-
treated NB4 cells which were collected at 19 time points and
untreated cell samples at 4 time points. After microarray
hybridization and data acquisition, gene expression data were
first subjected to a topology-preserving gene selection procedure
through self-organizing map (SOM) integrated singular value
decomposition (SVD). Following the procedure based on false
discovery rate (FDR) statistical inference, a total of 3,345 regulated
genes with characteristic patterns were selected (see Methods) and
further analyzed by component plane presentation (CPP)
integrated SOM [17–19]. As shown in Figure 2A, each
presentation illustrates a timepoint-specific transcriptome map,
permitting direct comparisons of transcriptome changes within/
between the control series and the fenretinide-treated series.
Comparing the control and treatment series, the observed
transcriptome changes before the 6-hour treatment (termed the
early stage) are mostly due to culture duration, implying that early-
stage effects induced by fenretinide are mainly biochemical, with
limited effects on transcriptional regulation. However, prominent
transcriptome changes become apparent after 8 hours of
treatment, as highlighted by genes mapped to neurons in
bottom-right corners (also termed Group 6 on the right panel of
Figure 2A). These genes are prominently up-regulated after the
early stage, representing a major transcriptome feature during
Coupling Redox to Apoptosis
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prominent effect of fenretinide treatment, it is logical to
speculate that modulation of these genes is a result of ROS
accumulation.
Transcriptional and functional features of clustered
genes characteristically highlighting oxidative stress-
mediated apoptosis. Our robust transcriptome approach
allows the clustering of genes with highly similar expression
patterns into the same or nearby neighboring neurons, as
illustrated in Figure 2B. This may facilitate many aspects of in-
depth mining of biological information relevant to the fenretinide-
induced apoptosis. We performed transcription factor binding site
(TFBS) enrichment analysis following hypergeometric distribution-
based multiple hypothesis tests to infer common transcriptional
features of clustered genes (see Methods). As illustrated by
representative neurons of Group 6 (Figure 2B), the transcription
factors NRF2, HSF1, ATF6 and ELK1 are significantly over-
represented respectively in neuron 40, 46, 47 and 49. NRF2 is
known to activate transcription of genes encoding antioxidative
proteins under oxidative stress [20,21], HSF1 is a transcription
factor responsible for expression of heat shock genes [22], ATF6 is
a key transcriptional activator of unfolded protein response (UPR)
[23], and ELK1 is involved in transcription of survival genes [24].
These data suggest that the genes in Group 6 are largely regulated
by stress-responsive transcription factors, highlighting the impact
of upstream oxidative signaling on downstream effects.
To further address functional importance of clustered genes, we
employed Gene Ontology (GO) for functional enrichment
analysis. Functional features with statistical significance were
revealed, depicting a relatively comprehensive view of oxidative
stress-mediated apoptosis. Among these features were genes
involved in transcriptional regulation, ribosome machinery,
oxidative stress, ER stress/UPR, ubiquitin-proteasome system,
and apoptosis (Figure 2C). Changes of genes involved in
transcriptional regulation appear to be logical for the admission
of malignant cells into programmed cell death, as indicated by up-
regulated DDIT3/CHOP, CEBPB, CEBPG, NFE2L1 and PHF1,
and down-regulated MYC and IKZF1. Reduced ribosome activity
may represent a direct response to stress-repressed overall protein
translation. Regulation of redox-related genes may account for
ROS reduction during later stages of fenretinide-induced
apoptosis. Up-regulation of a large number of ER stress- and
UPR-regulated genes was observed during the period from 6 to
24 hours after treatment (termed the intermediate stage), impli-
cating the occurrence of ER stress- and UPR-related defense
activities. Notably, we observed activation of genes involved in the
ubiquitin-proteasome system. Most of genes coding for the
proteasome apparatus were induced after the early stage,
promoting the degradation of overloaded unfolded/misfolded
proteins resulting from ER stress/UPR. Up-regulation of genes
encoding regulators/participants of apoptotic cascades (e.g.,
CASP7, BCLAF1, DEDD2, DAP3, STK17A, LAPTM5 and
MAGEH1) and down-regulation of negative apoptosis regulators
such as BCL2 and MPO were apparent during the intermediate
and late stages.
Additional molecular and cellular evidence for oxidative
stress-mediated apoptosis in fenretinide-treated
leukemia cells
The sequential involvement of ER stress/UPR and
mitochondria associated apoptotic activities. To validate
features revealed by transcriptome analysis and to identify
additional components of oxidative stress-mediated apoptosis, we
Figure 1. Cellular and molecular characterization of fenretinide-induced apoptosis in leukemia-derived NB4 cells. (A) Cell viability
was evaluated using an MTT assay after various doses of fenretinide for 48 hours. (B) Loss of mitochondrial membrane potential DYm with 1 mM
fenretinide treatment, as determined through rhodamine 123 and propidium iodide (PI) double staining, and followed by flow cytometry analysis. (C)
Apoptosis after 1 mM fenretinide treatment was evaluated by annexin V-specific antibody and PI double staining and flow cytometry analysis. (D)
Dynamic changes of ROS, as evaluated in cells stained with DCFH-DA and followed by flow cytometry analysis. Mean values6SD are plotted from
three independent experiments.
doi:10.1371/journal.pone.0007538.g001
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PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7538Figure 2. In-depth analysis of transcriptome changes induced by fenretinide in NB4 cells. (A) Illustration of transcriptome changes by
CPP-SOM. Each presentation illustrates a time-point specific transcriptome map, in which all the up-regulated (represented by neurons in red), down-
regulated (represented by neurons in blue) and moderately regulated (represented by neurons in yellow and green) genes are well delineated. Color
bar stands for expression values (log ratio with base 2), with brighter to denote the higher value. Presentations in control series are indicated by white
bar underneath, while those in fenretinide-treated series are partitioned into three stages: early, intermediate and late, as indicated by gray-graded
bar underneath. All the presentations are linked by positions, i.e., the same position represents the same neuron whose index is shown in the
enlarged grid ideogram on the right panel. Six recognizable regions obtained through hierarchical clustering based on pattern similarities are colored
coded as indicated. Genes in Group 6 are most prominently up-regulated during the apoptosis, representing an oxidative stress-responsive
transcriptome signature spectrum. (B) Illustration of expression patterns of genes in representative neurons of Group 6 through color-coded line
graphs and bar charts, as exemplified by neurons 46, 47, 40 and 49. Their corresponding PWM and/or GO enrichments are also indicated. (C) Major
functional features associated with oxidative stress-mediated apoptosis, as visualized by hierarchical clustering of representative genes.
doi:10.1371/journal.pone.0007538.g002
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shown in the left panel of Figure 3A, changes in protein levels of
the ER stress/UPR marker GRP78/HSPA5 and the stress-
inducible pro-apoptotic transcription factor CHOP/GADD153
were correlated with mRNA levels (Figure 2C). These genes and
proteins were specifically up-regulated during the intermediate
stage, providing further evidence that ER stress/UPR occurred
during this time frame. Additionally, the pro-apoptotic form of
CASP4, a ER stress-specific caspase [25], was dramatically
reduced at the late stage, implicating the involvement in
fenretinide-induced apoptosis. As shown in the right panel of
Figure 3A, mitochondria associated apoptotic caspase cascades
were activated at the late stage. Pro-apoptotic CASP9 was
reduced, whereas CASP3 was increased in its active form prior
to the late stage. Moreover, cleaved PARP was observed following
caspase cascade activation. In sum, the protein biochemical data
also support the notion that ER stress/UPR occurs at the
intermediate stage, while mitochondria-involved apoptosis occurs
mainly at the late stage.
Synergistic induction of cell apoptosis by fenretinide and
proteasome inhibitor. In fenretinide-treated cells, ROS
signaling may represent an essential stimulus at the early stage
of programmed cell death. To provide further evidence for ROS
signaling in apoptosis, we performed an antagonist assay using
vitamin C as the antioxidant. As shown in Figure 3B, vitamin C
treatment completely abrogated fenretinide-induced apoptosis in
NB4 cells. Genes encoding proteasome components were
significantly up-regulated during the intermediate and late
stages. Thus, we hypothesized that proteasome activity might
function as a defense mechanism coupled to the UPR for
unfolded/misfolded protein degradation to reduce the ER stress
burden [26]. Accordingly, proteasome activation may antagonize
the pro-apoptotic/apoptotic cascade. To explore this hypothesis,
we used the proteasome inhibitor MG132 to block proteasome
activity during fenretinide-induced apoptosis. As shown in
Figure 3C, a sub-cytotoxic concentration (0.2 mM) of MG132
together with a low dose of fenretinide (0.5 mM) induced
significant cell apoptosis within 48 hours, demonstrating
synergistic rather than antagonistic effects of the two compounds.
Converting oxidative signaling into downstream effects
through stress-responsive transcription factors as
highlighted by NRF2 and HSF1
Coordination between temporal-spatial changes of NRF2
and HSF1, and expression patterns of their potential target
genes. Our robust transcriptome profiling approach facilitated
the in-depth mining of biological information relevant to oxidative
Figure 3. Cellular and molecular evidence of oxidative stress-mediated apoptosis in fenretinide treated cells. (A) Western blot analysis
of ER stress/UPR related markers and apoptotic caspases upon 1 mM fenretinide treatment in NB4 cells. (B) Abrogation of fenretinide-induced
apoptosis by vitamin C. (C) Synergistic induction of cell apoptosis by proteasome inhibitor MG132 and fenretinide. Apoptosis was evaluated by
annexin V-specific antibody and PI double staining and flow cytometry analysis. The results represent the average of three independent
evaluations 6 SD.
doi:10.1371/journal.pone.0007538.g003
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transcription factors involved in gene regulation. Of
transcriptional regulators predicted, the stress-responsive
transcription factors NRF2 and HSF1 are of particular interest
for understanding how oxidative signaling is translated into
downstream effects. We therefore further investigated the
temporal abundance and spatial localization of these two stress-
responsive transcription factors during apoptosis. As demonstrated
in Figure 4A, protein levels of both NRF2 and HSF1 were
markedly elevated in nuclear extracts within 6 hours of exposure
to fenretinide, and their temporal abundance was differentiated
thereafter. NRF2 induction was extended beyond 24 hours
whereas HSF1 induction was terminated at this time point.
Similarly, immunofluorescence microscopy analyses revealed
marked accumulation of both factors in nuclei of cells treated
with fenretinide for 6 hours, compared to a diffuse distribution of
NRF2 and HSF1 in untreated cells (Figure 4B). Also, nuclear
gathering of NRF2 was sustained beyond the 24 hour treatment
period whereas that of HSF1 was terminated. Considering the
relatively low levels of ROS at 24 hour treatment (Figure 1D), the
inactivation of HSF1 is probably due to a reducing
microenvironment [22]. Moreover, the temporal-spatial changes
of NRF2 and HSF1 correlate well with regulatory patterns of their
potential target genes (Figure 4C). Up-regulated expression of
NRF2 potential target genes was extended to the late stage,
whereas gene expression of HSF1 potential targets was
unanimously terminated by the end of the intermediate stage.
Physical interactions between NRF2 and HSF1, and their
target genes upon activation. To explore whether NRF2 and
HSF1 are physically bound to their targets, we conducted
chromatin immunoprecipitation (ChIP) assays using antibodies
against NRF2 or HSF1. Based on the predicted TFBS of the
Figure 4. Coordinated regulation of stress-responsive transcription factors, i.e., NRF2 and HSF1, and their target genes. (A) Western
blot analysis of NRF2 and HSF1 from nuclear extracts of NB4 cells untreated or treated with 1 mM fenretinide at the indicated time points. ‘‘*’’
indicates the non-specific binding band. (B) Nuclear translocation of NRF2 and HSF1 following 1 mM fenretinide treatment in NB4 cells, as visualized
by immunofluorescence microscopy (scale bars, 5 mm). (C) Illustration of expression patterns of genes potentially targeted by NRF2 and HSF1,
illustrated in the left and right panel, respectively. (D) ChIP combined with PCR assays to validate the physical interaction between transcription
factors (i.e., NRF2 and HSF1) and their target genes. Total: total input; IgG: ChIP reaction with IgG antibody as a control; DNAJB6
#: primers designed
from non-TFBS region of the gene DNAJB6.
doi:10.1371/journal.pone.0007538.g004
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were designed using ChIP products of either NRF2 or HSF1 as
DNA templates. As illustrated in the left panel of Figure 4D, genes
with the predicted TFBS of NRF2 (i.e., FTL, NQO1, TXNRD1,
GCLM and GCLC) are positive for NRF2 ChIP products, whereas
unrelated genes (i.e., LRRC, AFIM and PAX7) are negative in the
same products. Although a basal level of NRF2 binding was
observed in untreated ChIP products, most of the predicted genes
revealed significantly stronger signals in treated samples. Likewise,
ChIP-PCR assays of HSF1 revealed similar results (Figure 4D,
right panel). Notably, primers designed from the TFBS region
revealed prominent bands in HSF1 ChIP products, whereas those
from the non-TFBS regions of the same genes revealed absent
signals (e.g., DNAJB6 vs. DNAJB6
#). Altogether, our evidence
indicates that NRF2 and HSF1 are activated upon ROS
accumulation by the end of the early stage, converting oxidative
signaling into downstream effects by directly acting on their target
genes. NRF2 activation extends to the late stage, while HSF1
activity is terminated by the end of the intermediate stage.
Functional relevance of NRF2 and HSF1 activation to
oxidative stress-mediated apoptosis in cancer
cells. Potential targets of NRF2 are mostly represented by
genes encoding antioxidant proteins or enzymes (Figure 4C) to
buffer the intracellular redox activities, such as FTL, NQO,
TXNRD, GCLM and GCL. Activation of NRF2 upon the
formation of oxidative signaling at the early stage enhances
expression of antioxidant genes, which may consequently result in
gradual ROS reduction at the intermediate stage, and moderate
ROS levels at the late stage (Figure 1D). Potential targets of HSF1
are largely represented by genes encoding UPR-related
chaperones (Figure 4C) such as HSPA8, HSPH1, HSPA1A,
HSPA9B, DNAJA1, DNAJB1, DNAJB6 and SERIPINH1. HSF1
activation and their target genes appear to be transient, providing
additional evidence that UPR observed in fenretinide-treated cells
occurs during the intermediate stage. Transient modulation of
UPR is probably important for oxidative stress-mediated apoptosis
in cancer cells, based on the fact that many of these UPR-related
chaperones are functionally inhibitory to pro-apoptotic/apoptotic
cascades [27]. Therefore, termination rather than preservation of
UPR prior to the late stage where most apoptotic activities occur is
probably essential for effective progression of apoptosis. In
addition to chaperone genes, several pro-apoptotic/apoptotic
genes are also regulated by HSF1, including DEDD [28] and
BAG3 [29]. Since the up-regulation of these genes is also
terminated at the end of the intermediate stage, it is tempting to
assume that they are involved in upstream activities of pro-
apoptotic/apoptotic cascades.
Substantial impact of NRF2 and HSF1 on stress-responsive
transcriptome signatures relevant to oxidative
stress-mediated apoptosis
Fenretinide-induced apoptosis in cancer cells occurs in response
to oxidative stress, and is orchestrated by stress-responsive
transcription factors, as highlighted by the modulation of a large
number of stress-responsive genes. Typically, these stress-respon-
sive genes are represented by those clustered in Group 6
(Figure 2A). Accordingly, we speculated that genes in Group 6
might represent a signature spectrum characteristic of cancer cells
undergoing oxidative stress-mediated programmed cell death
rather than survival upon stress stimulus. To validate this
assumption, and to evaluate the potential impact of NRF2 and
HSF1 on the assumed signature spectrum, we comparatively
overlapped genes in Group 6 with several sets of expression data
relevant to various stress responses under non-apoptotic conditions
[30] and our previously published expression data relevant to
ATO/RA-induced differentiation/apoptosis of NB4 cells [18].
Through hierarchical clustering followed by integration of
genomic TFBS information, stress-responsive transcriptome fea-
tures under apoptotic or non-apoptotic conditions were displayed
(Figure 5). By comparing these features across all the conditions,
the signature spectrum can be further partitioned into four
categories (I–IV). Modulation of genes in category I is attributed
largely to HSF1 activation, as also indicated by prominent up-
regulation under heat shock. HSF1 activation under non-apoptotic
heat shock conditions appears to be sustained rather than
transient. Modulation of genes in category II appears to be more
complex, probably because they are orchestrated by multiple
stress-responsive transcription factors such as CHOP and XBP1,
as implicated by the observed multifaceted TFBS composition.
Our data suggest that this gene category is also involved in the ER
stress/UPR occurring at the intermediate stage of oxidative stress-
mediated apoptosis, based on expression patterns as well as
functional annotations. Genes in category III are those directly
involved in redox signaling during the intermediate and late stages,
as highlighted by significant enrichment of NRF2 and its co-factor
MAF. Activation of genes encoding subunits of the proteasome
apparatus is one of the most prominent features in this study.
These genes are exclusively clustered in category IV. TFBS
analysis implicates that genes in this category are modulated by
ELK1.
Discussion
Cancer cells possess unique features not found in normal cells,
which can be exploited for therapeutic design. The oxidative
microenvironment of malignant cells is of particular interest.
Cancer cells are often sensitive to pharmacological agents that
affect the intracellular redox balance, favoring the genesis of
oxidative stress and subsequent cell apoptosis. To understand how
oxidative signaling is converted into programmed cell death and to
develop more sophisticated protocols preferentially targeting
cancer cells with minimal cytotoxicity to normal cells, we
performed a comprehensive analysis of oxidative stress-mediated
apoptosis in leukemia-derived NB4 cells sensitive to fenretinide
apoptotic effect through a systems approach integrating methods
of experimental and computational biology together with robust
tools of data mining.
In this study, we have delineated a global network with the
temporal-spatial relationships at both the transcriptional and
functional levels using a systems approach integrating experimen-
tal and computational biology. Our results depict a typical process
of oxidative stress-mediated apoptosis in cancer cells wherein
stress-responsive transcription factors play prominent roles in the
configuration of the underlying molecular networks (Figure 6).
The rapid generation of ROS at the early stage is probably a
biochemical process with minimal involvement of transcriptional
regulation. When ROS reaches a certain threshold level, stress-
responsive transcription factors appear to be responded. Nuclear
translocation of NRF2 and subsequent induction of its target genes
via antioxidant response element (ARE) may function to buffer
oxidative stress response during the intermediate and late stage,
whereas nuclear accumulation of HSF1 and thus activation of its
target genes via heat shock element (HSE) may contribute to the
occurrence of ER stress/UPR at intermediate stage, as implicated
by induction of ER-localized chaperones, repression of protein
translation and enhancement of ubiquitin-proteasome system. The
sequential involvement of ER stress/UPR and mitochondrial
associated apoptosis at the late stage is implicated separately by
Coupling Redox to Apoptosis
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stress-specific caspase CASP4, and disruption of mitochondria
transmembrane potential (DYm) and activation of caspase
cascades. Moreover, we provide solid evidence that oxidative
stress is translated into downstream effects through stress-
responsive transcription factors as highlighted by NRF2 and
HSF1. Activation of NRF2 and thus its target genes may therefore
contribute to reduction of ROS levels, as observed during the
intermediate and late stage, whereas activation of HSF1 and thus
its target genes may contribute to the transient occurrence of
UPR. Although detailed relationships between UPR and subse-
quent cell apoptosis remain to be clarified, UPR termination prior
to the late stage is probably essential for the effective activation
of apoptosis. Notably, dynamic changes in ROS levels are of
well relevance to not only the initiation of pro-apoptotic CHOP
activities, but also to expression pattern of NRF2-regulated
oxidative stress genes and HSF1-regulated ER stress genes
during fenretinide-induced apoptosis (Supplementary Figure S2).
Although these two sets of stress-responsive genes are individually
considered as regulators of cellular defense mechanisms, their
coordinated regulation in such manner as consistent activation of
NRF2 targets and transient activation of HSF1 targets can be
critical for the effective progression of apoptosis in response to
fenretinide stimuli. Although exploring whether blocking specific
transcription factors affects apoptosis is straightforward, our
comparative transcriptome data of various stress responses clearly
show that stress-relevant transcriptome features of fenretinide-
treated NB4 cells can be recognized as a signature spectrum
characteristic for oxidative stress-mediated apoptosis in cancer
cells. Moreover, our evidence indicates that the temporal-spatial
coordination of NRF2 and HSF1 in gene regulation plays an
essential role in the configuration of this signature spectrum.
Choosing fenretinide as a ROS-inducing agent in cancer cells
may have a number of advantages over other commonly-known
oxidative stressors, such as hydrogen peroxide (H2O2) or ATO.
H2O2 or ATO may cause extensive cellular damage while exerting
Figure 5. Prominent impact of NRF2 and HSF1 on transcriptome signatures underlying oxidative stress-mediated apoptosis in NB4
cells. Stress-related expression data were assembled and displayed through hierarchical clustering. TFBS information for each transcription factor is
integrated on the left of the display, with putative hits marked in red. Various conditions are indicated at the top of the display. Three stress
responses were all induced below the threshold where significant lethality occurred. Heat shock was induced in HeLa, fibroblast and K562 cells;
Endoplasmic reticulum stress was induced in HeLa cells with the glycosylation inhibitor tunicamycin or thiol reducing agent DTT, and in fibroblasts
with DTT; Oxidative stress was induced in HeLa cells with H2O2 or with menadione, and in fibroblasts with menadione. ATRA, ATO and ATRA/ATO-
combined treatments induce differentiation, apoptosis, and differentiation/apoptosis in NB4 cells, respectively. Also shown is relative expression of
genes in normal hematopoietic CD34
+ cells with fenretinide treatment compared to untreated control.
doi:10.1371/journal.pone.0007538.g005
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PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7538Figure 6. Ideogram illustrating temporal-spatial relationships among major stress-responsive events relevant to oxidative stress
mediated apoptosis in NB4 cells. Early, intermediate and late stage apoptosis and their characteristic events are indicated on the bar underneath.
Genes/proteins up-regulated are marked in red, and those down-regulated are marked in blue. Genes/proteins regulated at levels other than the
transcriptional or translational level are marked in black. Computationally predicted transcription factors are framed in pink. Relevant cellular
compartments are also indicated in the ideogram.
doi:10.1371/journal.pone.0007538.g006
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ever, fenretinide has shown to increase intrinsic ROS levels with
minimal in vivo side effects, probably by interacting with specific
cell membrane or cytoplasmic receptors with minimal impacts on
other non-related molecules [31]. Patients undergoing long-term
clinical trials with fenretinide treatment exhibit minimal side
effects including impaired night vision adaptation and dry skin,
which readily disappear after treatment cessation [32]. Fenretinide
is more effective, and possibly more specific in inducing
transcriptome changes relevant to oxidative stress-mediated
apoptosis compared to oxidative stressors such as ATO
(Figure 5). Our previous work has characterized the transcriptome
features of ATRA-induced differentiation and ATO-induced
apoptosis in NB4 cells [18], and the results of the present study
have allowed us to perform a detailed comparison of the
expression patterns between these three compounds. Comparing
the transcriptome between ATRA-induced differentiation and
fenretinide-induced apoptosis in NB4 cells, we found that
fenretinide treatment series were dissimilar to ATRA treatment
series, possibly reflecting the distinct biological action of these two
retinoids (Supplementary Figure S3). Among our assumed
signature spectrum characteristic for oxidative stress-mediated
apoptosis, however, overlaps of genes between ATO-induced
apoptosis or ATRA/ATO-induced differentiation/apoptosis and
fenretinide-induced apoptosis in NB4 cells were not trivial
(Figure 5). Based on these observations, we can speculate that
fenretinide functions more in an ATO-like manner to trigger
apoptosis, rather than in an ATRA-dependent manner to induce
differentiation, although the possibilities that some ATRA-like
indirect effects in oxidative stress-mediated apoptosis can not be
excluded.
Choosing fenretinide as an anti-tumor agent may also be
superior to the conventional chemotherapeutic agent, cytosine
arabinoside (Ara-C), in terms of the cytotoxicity. To evaluate the
potential cytotoxicity of fenretinide and Ara-C to normal cells, we
isolated normal hematopoietic CD34
+ cells from four non-
leukemic donors (i.e., ND1, ND2, ND3, and ND4). As illustrated
in Supplementary Figure S4, the viability (marked by both
Annexin V-FITC and 7-ADD negative) was almost unchanged
between 2.5 mM fenretinide-treated and untreated cells, whereas
the viability after the treatment of 2.5 mM Ara-C was considerably
reduced. As summarized in Table 1, normal hematopoietic
CD34
+ cells were highly resistant to fenretinide, even at the
higher dose. Moreover, no significant difference was observed with
the increase of fenretinide concentration, with the relative viability
of 97.865.4% at 2.5 mM and 94.266.2% at 5 mM (P=0.414). In
contrast, the relative viability of CD34
+ cells in Ara-C treated
samples (43.0610.6%) were significantly lower than that in
samples treated by fenretinide of the same concentration
(P=9.04610
25). These results, together with the high sensitivity
of leukemia-derived cell lines NB4, U937, and HL60 to fenretinide
(Supplementary Figure S1), demonstrated that fenretinide, unlike
the conventional chemotherapeutic agents, could specifically
target cancer cells while maintaining its minimal cytotoxicity to
normal cells. Since genes in Group 6 represent a fenretinide-
induced signature characteristic of cancer cells undergoing
oxidative stress-mediated apoptosis (Figure 2A and Figure 5), we
speculate that those genes in expression should also reflect the
differences between tumor and normal cells in responses to
fenretinide. To such end, we generated transcriptome profile of
normal hematopoietic CD34
+ cells with and without fenretinide
treatment, and compared it with genes in Group 6 exclusively
induced by fenretinide in NB4 cells. As revealed by gene set
enrichment analysis (GSEA) [33], we observed significant
differences in expression of these genes between fenretinide-
treated NB4 cells and fenretinide-treated normal CD34
+ cells
(Supplementary Figure S5A). Rather than the coordinated
induction of genes in Group 6 in fenretinide-treated NB4 cells,
those genes were predominantly inactive in fenretinide-treated
normal CD34
+ cells, suggesting the absent responses of normal
cells to fenretinide. As shown in Supplementary Figure S5B,
similar results were also obtained by GSEA of those genes in
Figure 5. Collectively, the presence of oxidative stress-responsive
apoptotic signature could account for the specificity of fenretinide
in targeting cancer cells while sparing normal cells.
Fenretinide is known as a remarkable chemopreventive agent,
and clinical data have provided evidence that it can significantly
reduce the risk of second breast cancer in premenopausal women,
and may be capable of eliminating cancer cells at early stages [34].
Elevated ROS generation seems to be associated with cancer cells
and with early stages cancer cells. It has recently been reported
that oncogenic transformation of epithelial cells causes ROS
accumulation, which renders the cells sensitive to a chemopre-
ventive natural compound that can preferentially increase ROS
generation and cause apoptosis in cancer cells [35]. Furthermore,
recent studies have shown that early-lineage leukemic cells rather
than normal hematopoietic cells are sensitive to ROS-generating
agents [36]. Accordingly, it is of significant value to further
evaluate whether fenretinide exerts apoptotic effects on cancer
cells at early stages. Of note, proteasome inhibitors appear to be
another category of agents that can induce apoptosis in early-
lineage leukemic cells [37]. In this study, we have clearly
demonstrated that the proteasome inhibitor MG132 induces
leukemia cell apoptosis synergistically with fenretinide. More
Table 1. Relative viability of normal hematopoietic CD34
+ cells isolated from 4 donors in response to fenretinide or Ara-C
compared to untreated control.
Normal donors Relative viability (%)
2.5 mM Ara-C 2.5 mM fenretinide 5 mM fenretinide
ND1 50.2 99.3 99.2
ND2 36.8 90.2 85.5
ND3 53.5 102.9 94.3
ND4 31.4 98.9 97.9
Mean6SD 43.0610.6 97.865.4 94.266.2
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mechanistic links among different stress-responsive events may
provide a broader view of oxidative stress-mediated apoptosis in
cancer cells. This information may allow us to eventually develop
more sophisticated protocols specifically targeting cancer cells and
perhaps cancer cells at early stages. Our results identifying NRF2
and HSF1 as prominent mediators of oxidative signaling is of
particular interest. Whether early stage cancer cells possess similar
mechanisms under fenretinide treatment remains to be elucidated.
Methods
Evaluations of growth inhibition, cell apoptosis, and ROS
accumulation in fenretinide treated leukemic cells
Leukemia-derived cell lines NB4 [38], U937 [39] and HL60
[40] were cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum (Gibco). Fenretinide was purchased from
Sigma and dissolved in ethanol at a 10 mM stock solution. Cell
viability was evaluated by MTT assay, and growth inhibition was
determined by the number of viable cells in treated samples
compared to untreated samples. For a treatment time series, NB4
cells were treated with 1 mM fenretinide and harvested at 0, 0.5, 1,
2, 4, 6, 12, 24, 48, and 72 hours. Mitochondrial membrane
potential (MMP, DYm) was evaluated through rhodamine 123 and
propidium iodide (Sigma, St. Louis, MO) staining, followed by
flow cytometry analysis. Apoptosis was determined using an
ApoAlert Annexin V staining kit (Clontech) and followed by flow
cytometry. To evaluate ROS changes during the time course,
samples were stained with 10 mM DCFH-DA in the dark for
20 min at 37uC [31].
Transcriptome analysis of fenretinide-induced apoptosis
in cancer cells
Array hybridization, topology-preserving gene selection
through self-organizing map (SOM) integrated singular
value decomposition (SVD), and gene clustering by
component plane presentation (CPP) integrated
SOM. Fenretinide treated NB4 cells were harvested at 0.25,
0.5, 1, 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and
60 hour, and followed by RNA preparations. Simultaneously,
untreated NB4 cells were also collected after 0, 8, 12 and 15 hours
in culture. Array fabrication, RNA isolation, labeling, and
hybridization were performed as previously described [18,19].
After hybridization, data acquisition was conducted using a laser
scanner (Axon) and then normalized by intensity-dependent global
Lowess regression. A primary expression matrix with expression
values (log ratios with base 2) of 8,044 analyzable cDNA elements
across 23 samples was constructed and subsequently applied to a
topology-preserving gene selection procedure [41]. The selection
procedure consists of three major steps: SOM transformation,
SVD decomposition followed by feature recognition, and gene
selection based on false discovery rate (FDR) estimation (see
Methods S1). Under the FDR of 0.09, 228 neurons representing
3,345 regulated genes were selected. For gene clustering and
visualization, those well-selected genes were subjected to CPP-
SOM [17–19,42] with 50 (1065) neurons (see Data S1).
Transcription factor binding site (TFBS) enrichment and
functional annotation studies. Two major steps were
involved in TFBS enrichment studies: transcriptional regulatory
signature database (TRSD) construction and statistical evaluation
of TFBS enrichment. For the construction of TRSD, putative
promoter sequences for about 25,000 RefGene reference
sequences, each spanning 2-kb upstream and 200 bp
downstream of putative transcription start site, were extracted
from the UCSC genome browser (March 2006 build) and mapped
to Entrez Gene (NCBI) for unique gene identification. These
putative promoter fragments, representing 18,284 unique genes,
were then scanned for putative TFBSs by a position weight matrix
(PWM)-based MATCH software program [43]. Through a rank-
based threshold of maximal 2,500 hits per PWM, a genome-wide
TRSD was constructed, containing 493 transcriptional regulatory
signatures/PWMs with the average of 1,686 potential target genes
per PWM. Using this TRSD, we assessed each neuron for the
significant enrichment of each transcriptional regulatory signature
under the hypergeometric distribution. Under this distribution
model, we calculated neuron-specific p-values against each
regulatory signature using the entire EntrezGene as the
background, with each p-value representing the likelihood of a
specific signature enriched in the neuron. Afterward, the
Benjamini-Hochberg (BH) derived step-up procedure of FDR
was applied to account for multiple hypothesis testing. The
calculations are summarized as follows: let the observed raw
p-values be p1ƒp2ƒƒpL (L=493), then the q values










Accordingly, q values were utilized to determine the significance
of the PWM enrichments per neuron.
For functional annotation of genes clustered in each neuron, we
utilized the database of Gene Ontology (GO) (ftp://ftp.ncbi.nih.
gov/gene/DATA/gene2go.gz). We carried out similar enrichment
analyses through the hypergeometric distribution and followed by
BH step-up procedure for q values, as described above.
Comparison of stress-related transcriptome features in
apoptotic and non-apoptotic conditions. Several previously
published sets of stress-related expression data under non-
apoptotic conditions [30] and ATO/RA-induced differentiation/
apoptosis expression data [18] were subjected to our SOM-SVD
gene selection procedures. After gene selection, those genes which
overlapped with Group 6 (Figure 2A) were further utilized for
significant TFBS recognition in the promoter regions using our
TRSD. Overlaps were organized through hierarchical clustering
and followed by integration of putative hits of those significantly
enriched transcription factors (i.e., HSF1, NRF2, MAF, ELK1,
ATF6, XBP1 and CHOP), revealing four distinct categories (I–IV)
with characteristic TFBS compositions (see Data S2).
Cellular and molecular validations of features recognized
through transcriptome analysis of oxidative stress-
mediated apoptosis in cancer cells
Western blot analyses were performed using specific antibodies
for GRP78 (Santa Cruz Biotechnology, Santa Cruz, CA),
GADD153/CHOP/DDIT3 (Abcam, Cambridge, MA), CASP4
(BD Biosciences Pharmingen, San Diego, CA), CASP9 (Cell
Signaling Technology, Beverly, MA), CASP3 (Cell Signaling
Technology, Beverly, MA), PARP (Santa Cruz Biotechnology,
Santa Cruz, CA), NRF2 (Santa Cruz Biotechnology, Santa Cruz,
CA), HSF1 (Santa Cruz Biotechnology, Santa Cruz, CA) and
ACTIN (Oncogene, Fremont, CA) on either total protein lysates
or nuclear extracts. For ROS antagonist assays, NB4 cells were
treated with 1 mM fenretinide and/or 100 mM of the antioxidant
vitamin C (ascorbic acid sodium salt; Sigma) for 24 hours, and
then subjected to apoptosis evaluation. For proteasome antagonist
assays, NB4 cells were treated with 0.5 mM fenretinide and/or
Coupling Redox to Apoptosis
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48 hours prior to apoptosis evaluation. For cellular localization
analysis, NRF2 and HSF1 were visualized by immunofluorescence
microscopy. Chromatin immunoprecipitation (ChIP) was carried
out using antibodies against NRF2 and HSF1, as described
previously [27,44]. Immunoprecipitates were subjected to quan-
titative real-time PCR to validate potential TFBSs in gene
promoters computationally which were identified by integrative
analysis, as described in the previous sections.
Evaluation of cytotoxicity in fenretinide-treated normal
hematopoietic CD34
+ cells
Fresh bone marrow cells were obtained from 4 normal donors
(i.e., ND1, ND2, ND3, and ND4; see Table 1) with informed
consent according to the Declaration of Helsinki and approval of
Institutional Review Board at Ruijin Hospital affiliated to
Shanghai Jiao Tong University School of Medicine. CD34
+
cells were isolated using EasySepH Human CD34 Positive
Selection kit (Stem Cell Technologies, Vancouver, BC, Canada)
according to the manufacturer’s instructions, and then were
separately treated with 2.5 mMa n d5mMf e n r e t i n i d e ,a n da l s o
with chemotherapeutics as comparisons, 2.5 mMc y t o s i n e
arabinoside (Ara-C; Sigma, St. Louis, MO). After 24 hours of
treatment or un-treatment, the cells were then subjected to
double-labeling with 7-aminoactinomycin (7-AAD; Molecular
Probes, Eugene, OR) and AnnexinV-FITC (BD Pharmingen,
San Diego, CA), followed by flow cytometry analysis. Viable cells
were counted from both Annexin V-FITC and 7-ADD negative
(i.e., no measurable apoptosis). The relative viable was calculated
as viable cells with the treatment divided by those viable cells
without the treatment.
Transcriptome profiles of normal hematopoietic CD34
+
cells with and without fenretinide treatment, and
compared with stress-responsive transcriptome
signature induced by fenretinide in NB4 cells
Total RNAs of CD34
+ cells from a normal donor (i.e., ND1)
treated with 1 mM fenretinide or left untreated for 12 hours were
amplified and labeled with biotin according to the standard
AffymetrixH protocol. The fragmented, biotinylated cDNA was
then subjected to hybridization with the GeneChipH Human
Genome-U133 plus 2.0 array (Affymetrix, Santa Clara, CA). Raw
expression data were normalized using Affymetrix MAS 5.0
algorithm in R (Bioconductor). Detection call-based filter [45] was
applied to remove all the probesets whose expression values were
consistently below an empirically-determined value of minimum
sensitivity, which were evaluated according to the 95
th percentile
of all the ‘Absent’ call-flagged signals of the entire dataset.
Following the normalization and filtering, gene set enrichment
analysis (GSEA) [33] was utilized to determine the degree to which
genes in Group 6 (Figure 2A) as well as genes in Figure 5 are
overrepresented at the top or bottom of ranked gene lists from
highest to lowest expression in normal hematopoietic CD34
+ cells
with fenretinide treatment compared to those without fenretinide
treatment.
Publicly deposited microarray data
The microarrays used to generate time-series transcriptome
profilings of fenretinide-treated versus untreated NB4 cells are
in accordance with MIAME guidelines, and are available
at the Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo/) public database under accession number
GSE16578.
Supporting Information
Methods S1 More detailed materials related to data mining in
this study
Found at: doi:10.1371/journal.pone.0007538.s001 (0.07 MB
DOC)
Figure S1 Cellular and molecular characterization of fenretinide-
induced apoptosis in leukemia-derived NB4, HL60, and U937 cells.
(A) Viable cells rate occurring upon the 48 hours treatment of a
series of fenretinide concentration. (B) Loss of mitochondrial
membrane potential in response to fenretinide treatment, as
determined through rhodamine 123 and propidium iodide (PI)
double staining, and followed by flow cytometry analysis. (C) Effects
offenretinideonROSgenerationafterthe treatmentof12 hours,as
evaluated by DCFH-DA staining prior to analysis by flow
cytometry. Each point is the mean of three experiments6SD.
Found at: doi:10.1371/journal.pone.0007538.s002 (0.63 MB TIF)
Figure S2 Dynamics of intracellular ROS level, pro-apoptotic
CHOP mRNA, and expression pattern of NRF2-regulated-
oxidative-stress genes and HSF1-regulated-ER-stress genes during
fenretinide-induced apoptosis. Changes of intracellular ROS are
displaying left-skewed bell-shape curve (in blue). The accumula-
tion of ROS at the early stage (within 6 hours) not only accounts
for the biological mechanism of fenretinide, but also initiates
stress-inducible pro-apoptotic transcription factor CHOP activities
(in light purple) and incurs the stress-responsive events, as
highlighted by activation of stress-responsive transcription factors
NRF2 and HSF1 and the subsequent modulation of NRF2-
regulated-oxidative-stress targets (curve in cyan) and HSF1-
regulated-ER-stress targets (curve in dark purple). The average
expression pattern of NRF2 targets and HSF1 targets are plotted
based on genes in left panel and right panel of Figure 4C,
respectively.
Found at: doi:10.1371/journal.pone.0007538.s003 (0.90 MB TIF)
Figure S3 Illustration of the transcriptome changes in fenreti-
nide-treated series and ATO or/and ATRA-treated series in NB4
cells by component plane presentation integrated self-organizing
map (CPP-SOM). HPR: fenretinide; ATO: arsenic trioxide;
ATRA: all-trans retinoic acid.
Found at: doi:10.1371/journal.pone.0007538.s004 (3.92 MB TIF)
Figure S4 Representative flow cytometry dot plots illustrating
the effects of fenretinide and Ara-C on normal hematopoietic
CD34+ cells. Also shown is the proportion of those viable cells
marked with both Annexin V-FITC and 7-ADD negative (i.e., no
measurable apoptosis).
Found at: doi:10.1371/journal.pone.0007538.s005 (0.31 MB TIF)
Figure S5 GSEA analysis of (A) genes in Group 6 (Figure 2A) and
(B) genes in Figure 5 regarding to transcriptome profiles of normal
hematopoietic CD34+ cells with fenretinide treatment compared to
those without treatment. In the contrast to coordinated induction in
fenretinide-treated NB4 cells, those genes were predominantly
inactive in fenretinide-treated normal CD34+ cells.
Found at: doi:10.1371/journal.pone.0007538.s006 (0.52 MB TIF)
Data S1 Gene expression matrix (3,345623) identified by SOM-
SVD and analyzed by CPP-SOM in fenretinide-induced apoptosis
of NB4 cells.
Found at: doi:10.1371/journal.pone.0007538.s007 (2.03 MB
XLS)
Data S2 Overlaps among stress-related genes between apoptotic
and non-apoptotic conditions with characterersitic TFBS
information.
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